Change in vaccine vial monitor (VVM) assignment for GlaxoSmithKline Rotarix product

Author: WHO


This information bulletin addresses the implications and required guidance associated with the upcoming scheduled shift in vaccine vial monitor (VVM) of the GlaxoSmithKline Biologicals SA (GSK) Rotavirus vaccine, Rotarix®, from VVM type 14 (VVM14) to VVM type 7 (VVM7). The information below is intended for WHO/UNICEF staff, as well as Expanded Program for Immunization (EPI) managers or other partner agencies which support immunization programmes.


Type Document
Language English
Country Not Specified
Publisher WHO
Year 2017
Added by Moderator
Added on 8 April 2019 13:14:59
Hits: 20
Rating Summary:
0 based on 0 votes
Add to Favourites